North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial

NCT04167085

Epistaxis

COMPLETED PHASE4

Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)

NCT03152019

Hemorrhagic Hereditary Telangiectasia (HHT)

COMPLETED PHASE2

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT04139018

Hereditary Hemorrhagic Telangiectasia

COMPLETED PHASE2

Nasal Compression Device Study for Epistaxis

NCT05789264

Epistaxis Nosebleed

RECRUITING NA

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

NCT02285634

Epistaxis Blood Pressure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

140 patients with moderate to severe epistaxis secondary to HHT will be randomized to receive one of four intranasal sprays for a period of 12 weeks and then followed for an additional 12 weeks off therapy. Enrollment will occur over a period of 18-36 months. The primary endpoint will be the frequency of epistaxis. Secondary endpoints will include duration of epistaxis, the Hoag Epistaxis Severity Score (ESS), a quality of life survey, satisfaction with treatment, hemoglobin and ferritin levels, transfusion requirements, and treatment failure. The sprays will be: saline spray (Placebo); estriol 0.1% in methylcellulose suspension (EST); tranexamic acid 10% in saline (TA), and bevacizumab 1% in saline (BEV). All sprays will be applied to the nasal mucosa by an identical spray bottle at a dose of 0.1 ml per nostril twice daily (total dose of 0.4 ml daily). Thus, the delivered doses will be: EST, 0.4 mg/day; TA, 40 mg/day; BEV, 4 mg/day.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Telangiectasia, Hereditary Hemorrhagic Epistaxis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo spray

sterile saline

Group Type PLACEBO_COMPARATOR

Sterile saline

Intervention Type DRUG

0.9%, 0.1 ml spray in each nostril bid

Bevacizumab spray

bevacizumab 1%

Group Type ACTIVE_COMPARATOR

Bevacizumab

Intervention Type DRUG

1% solution in saline, 0.1 ml spray in each nostril bid

Estriol spray

Estriol 0.1%

Group Type ACTIVE_COMPARATOR

Estriol

Intervention Type DRUG

0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid

Tranexamic acid spray

tranexamic acid 10%

Group Type ACTIVE_COMPARATOR

Tranexamic Acid

Intervention Type DRUG

10% solution in saline, 0.1 ml spray in each nostril bid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sterile saline

0.9%, 0.1 ml spray in each nostril bid

Intervention Type DRUG

Bevacizumab

1% solution in saline, 0.1 ml spray in each nostril bid

Intervention Type DRUG

Estriol

0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid

Intervention Type DRUG

Tranexamic Acid

10% solution in saline, 0.1 ml spray in each nostril bid

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Saline Avastin Vascular endothelial growth factor (VEGF) inhibitor Estrogen Lysteda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A diagnosis of definite or possible HHT by the Curacao criteria (Shovlin 2000) or a positive DNA test for HHT (as characterized by a disease causing mutation in the gene coding for endoglin, activin like kinase 1, or SMAD-4). According to the Curacao criteria, a definite diagnosis of HHT is defined as having at least 3 of the following criteria while a possible diagnosis is defined as 2 criteria:

1. Spontaneous and recurrent epistaxis.
2. Multiple telangiectasias at characteristic sites (lips, oral cavity, fingers, nose).
3. Visceral lesions such as gastrointestinal telangiectasias and arteriovenous malformations (AVM) in lung, brain, spine and liver.
4. A history of definite HHT in a first degree relative using these same criteria.
2. Epistaxis of at least 1 minute (on average) and which occurs at least once weekly when averaged during the preceding 8 weeks.
3. Epistaxis severity score (ESS) of at least 3.0.
4. Age of at least 18 years.
5. Written and informed consent obtained prior to study entry.
6. Subject is able and willing to return for outpatient visits.
7. The epistaxis is considered to be clinically stable during the past 8 weeks in the clinical judgment of the investigator (i.e. no major changes in frequency or duration of epistaxis or in transfusion requirements).
8. Negative pregnancy test at enrollment.

Exclusion Criteria

1. Allergy to any of the active treatment agents or their spray additives.
2. Estimated life expectancy less than 1 year.
3. A psychiatric or substance abuse problem that is expected to interfere with study compliance.
4. History of deep venous thrombosis (DVT), pulmonary embolism (PE), acute myocardial infarction (MI), arterial thromboembolism, or ischemic stroke in the past 6 months.6. History of receiving more than 12 units of red blood cells in the past 12 weeks.

7\. Presence of an untreated coagulopathy that is felt to be contributing to the 5. History of estrogen receptor positive breast cancer. epistaxis. 8. Presence of active disseminated intravascular coagulation. 9. Uncontrolled hypertension (systolic BP \>160 and/or diastolic BP \>100). 10. Presence of untreated brain AVM. 11. Presence of active malignancy in the brain, lung, or colon. 12. Presence of symptomatic heart failure. 13. Use of estrogens, epsilon aminocaproic acid, tranexamic acid, or thalidomide by any route for more than 1 week in the past 12 weeks. Any use of a VEGF inhibitor by any route in the past 24 weeks.

14\. Baseline use of the following anticoagulants is not allowed: warfarin or other vitamin K antagonists at any dose; unfractionated or low molecular weight heparins at standard doses for treatment of venous thromboembolism (VTE); or aspirin at \>325 mg/day. Baseline use of the following anticoagulants is allowed: heparins at standard doses for VTE prophylaxis; clopidogrel; or aspirin at ≤325 mg/day.

15\. Addition of new treatments for epistaxis in the past 12 weeks (including laser ablation of nasal telangiectasias and over the counter medications).

16\. Presence of another overt cause (e.g. overt gastrointestinal bleeding) that is felt to be significantly contributing to anemia.

17\. Lactating women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No